EFSA J. 2017 Oct 26;15(10):e05017. doi: 10.2903/j.efsa.2017.5017. eCollection 2017 Oct.
ECDC, EFSA and EMA have jointly established a list of harmonised outcome indicators to assist EU Member States in assessing their progress in reducing the use of antimicrobials and antimicrobial resistance (AMR) in both humans and food-producing animals. The proposed indicators have been selected on the basis of data collected by Member States at the time of publication. For humans, the proposed indicators for antimicrobial consumption are: total consumption of antimicrobials (limited to antibacterials for systemic use), ratio of community consumption of certain classes of broad-spectrum to narrow-spectrum antimicrobials and consumption of selected broad-spectrum antimicrobials used in healthcare settings. The proposed indicators for AMR in humans are: meticillin-resistant and 3rd-generation cephalosporin-resistant , resistant to aminoglycosides, fluoroquinolones and 3rd-generation cephalosporins, resistant to penicillin and resistant to macrolides, and resistant to carbapenems. For food-producing animals, indicators for antimicrobial consumption include: overall sales of veterinary antimicrobials, sales of 3rd- and 4th-generation cephalosporins, sales of quinolones and sales of polymyxins. Finally, proposed indicators for AMR in food-producing animals are: full susceptibility to a predefined panel of antimicrobials in , proportion of samples containing ESBL-/AmpC-producing , resistance to three or more antimicrobial classes in and resistance to ciprofloxacin in . For all sectors, the chosen indicators, which should be reconsidered at least every 5 years, are expected to be valid tools in monitoring antimicrobial consumption and AMR. With the exception of the proposed human AMR indicators, the indicators are in general not suitable to monitor the effects of targeted interventions in a specific sector, such as in a single animal species or animal production sector. Management decisions should never be based on these indicators alone but should take into account the underlying data and their analysis.
欧洲疾病预防控制中心(ECDC)、欧洲食品安全局(EFSA)和欧洲药品管理局(EMA)联合制定了一份统一的结果指标清单,以协助欧盟成员国评估其在减少人类和食用动物抗菌药物使用及抗菌药物耐药性(AMR)方面的进展。所提议的指标是根据成员国在发布时收集的数据选定的。对于人类而言,所提议的抗菌药物消费指标包括:抗菌药物总消费量(仅限于全身用抗菌药物)、某些类别的广谱抗菌药物与窄谱抗菌药物的社区消费量之比以及医疗环境中使用的选定广谱抗菌药物的消费量。所提议的人类AMR指标包括:耐甲氧西林金黄色葡萄球菌和耐第三代头孢菌素金黄色葡萄球菌、对氨基糖苷类、氟喹诺酮类和第三代头孢菌素耐药的大肠杆菌、对青霉素耐药的肺炎链球菌、对大环内酯类耐药的肺炎链球菌以及对碳青霉烯类耐药的鲍曼不动杆菌。对于食用动物,抗菌药物消费指标包括:兽用抗菌药物的总销售额、第三代和第四代头孢菌素的销售额、喹诺酮类的销售额以及多粘菌素的销售额。最后,所提议的食用动物AMR指标包括:猪源大肠杆菌对一组预定义抗菌药物的完全敏感性、含有产超广谱β-内酰胺酶/头孢菌素酶大肠杆菌的样本比例、鸡源大肠杆菌对三种或更多抗菌药物类别的耐药性以及鸡源弯曲杆菌对环丙沙星的耐药性。对于所有领域,所选指标预计将成为监测抗菌药物消费和AMR的有效工具,且应至少每5年重新审议一次。除了所提议的人类AMR指标外,这些指标一般不适用于监测特定领域(如单一动物物种或动物生产部门)针对性干预措施的效果。管理决策绝不应仅基于这些指标,而应考虑基础数据及其分析。